NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NasdaqGS:SPPI) of the November 21, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
The lawsuit was filed on September 21, 2016 in the U.S. District Court for the Central District of California on behalf of all those who purchased Spectrum securities between December 16, 2015 and September 16, 2016 ( “Class Period”). The case is Ayeni v. Spectrum Pharmaceuticals, Inc. et al, No. 2:16-cv-07074.
The lawsuit focuses on whether the Company and executives violated federal securities laws by failing to disclose that the FDA advised defendants not to submit a New Drug Application for Qapzola, questioning the clinical and statistical validity of the 611 and 612 studies’ results.
Request more information now by clicking here: www.faruqilaw.com/SPPI . There is no cost or obligation to you.
If you invested in Spectrum securities during the Class Period and would like to discuss your legal rights, visit www.faruqilaw.com/SPPI. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as lead plaintiff.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your case. All communications will be treated in a confidential manner.